Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic science

2868 - Detection of Therapeutic Targets in Carcinomas of Unknown Primary


10 Sep 2017


Basic science


Cancer Biology;  Carcinoma of Unknown Primary Site (CUP)


Britt Clynick


Annals of Oncology (2017) 28 (suppl_5): v595-v604. 10.1093/annonc/mdx391


B. Clynick1, B. Dessauvagie2, G. Strerrett2, N. Harvey2, S. Subramaniam3, J. Herron4, R. Allcock1, B. Guo1, C. Saunder5, W. Erber1, K. Meehan1

Author affiliations

  • 1 Biomedical Sciences, University of Western Australia, 6009 - Perth/AU
  • 2 Anatomical Pathology, PathWest, 6009 - Perth/AU
  • 3 General Surgery, Royal Perth Hospital, 6000 - Perth/AU
  • 4 Radiology, Sir Charles Gardiner Hospital, 6009 - Perth/AU
  • 5 Surgery, Fiona Stanley Hospital, 6150 - Perth/AU


Abstract 2868


Current cancer treatment paradigms are based on features of the primary tumour and extent of disease. Carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer in the absence of an identifiable primary tumour. As such it is difficult to determine the optimal treatment strategy and 5-year survival rates are less than 20%. This poor survival rate is due to both the unclassifiable metastatic malignancy and the use of empirical broad-spectrum chemotherapy. A shift towards personalising cancer management based on mutation profiling has been explored in many cancer types including CUP. Small studies have reported durable treatment responses in CUP patients receiving targeted therapies, specifically when EGFR and KIT variants are detected. The present study has explored whether biologically important oncogenic driver mutations and potentially actionable targets are present in CUP that have potential to better inform treatment decisions.


CUP cases (n = 32) diagnosed on histopathology criteria were selected for study. Sections were cut from paraffin blocks of formalin-fixed tissue and DNA isolated. Extracted DNA was amplified with the Ion AmpliSeq Cancer Hotspot panel and Oncomine Focus panel for the identification of biologically relevant and actionable mutations, respectively. Amplified DNA was sequenced using the Ion Torrent platform and data was processed using a stringent variant filtration pipeline.


Biologically relevant or therapeutically druggable variants were detected in 88% (n = 28) of cases. The most common variants were in TP53 (47%), KRAS (19%), MYC (6%), BRAF (6%) and CDKN2A (6%). There were potentially actionable targets in 14/32 (44%) cases, with the most common druggable variants being in the KRAS gene (exon 1) (6 cases) and MYC gene amplifications (2 cases).


This retrospective study successfully identified biologically relevant variants in 88% of CUP cases. 50% of these variants were potentially actionable with drugs currently approved for use in known primary cancer types or undergoing clinical trials. This would give a novel treatment option to patients with a currently incurable disease with poor survival. The data therefore supports the use of NGS at diagnosis to give biological insight into the drivers leading to the malignancy, and to allow consideration of novel targeted treatment options.

Clinical trial identification

Legal entity responsible for the study

Translational Cancer Pathology Laboratory




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.